ELVN · Enliven Therapeutics, Inc.
$58.92
-0.47 (-0.79%)
At close · Aug 20
Market Cap
$4.30B
Shares
73.27M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Richard Fair | M.B.A. President and Chief Executive Officer | $11,918,926 |
| Sam Kintz | M.B.A. Former President and Chief Executive Officer | $8,908,647 |
| Helen Collins | Chief Medical Officer | $3,501,699 |
| Ben Hohl | Chief Financial Officer | $3,443,173 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Sam Kintz | M.B.A. President and Chief Executive Officer | $5,461,660 |
| Helen Collins | Chief Medical Officer | $2,771,410 |
| Joseph P. Lyssikatos | Chief Scientific Officer | $2,734,410 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Sam Kintz | M.B.A. President and Chief Executive Officer | $8,279,032 |
| Helen Collins | Chief Medical Officer | $4,064,258 |
| Joseph P. Lyssikatos | Chief Scientific Officer | $4,010,749 |
| Rahul D. Ballal | Former President and Chief Executive Officer | $1,865,809 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Rahul D. Ballal | Former President and Chief Executive Officer | $1,149,681 |
| Sam Kintz | M.B.A. President and Chief Executive Officer | $723,839 |
| Helen Collins | Chief Medical Officer | $645,504 |
| Joseph P. Lyssikatos | Chief Scientific Officer | $535,770 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Rahul D. Ballal | President and Chief Executive Officer | $1,951,029 |
| Kenneth Attie | Chief Medical Officer | $1,621,940 |
| Michael P. Gray | Chief Financial Officer and Chief Operating Officer | $1,216,404 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Rahul D. Ballal | President and Chief Executive Officer | $625,596 |
| Michael P. Gray | Chief Financial Officer and Chief Operating Officer | $541,426 |
| Willem Scheele | Former Chief Medical Officer | $368,402 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Rahul D. Ballal | President and Chief Executive Officer | $2,026,369 |
| Michael P. Gray | Chief Financial Officer and Chief Operating Officer | $1,271,739 |
| Willem Scheele | Former Chief Medical Officer | $1,063,194 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Andrew Phillips, Ph.D. | Director | Resigned | 2026-01-07 |
| Scott Garland | Class I director | Appointed | 2026-01-07 |
| Richard Fair | member of the board of directors | Appointed | 2025-12-11 |
| Richard Fair | President and Chief Executive Officer | Appointed | 2025-12-11 |
| Rishi Gupta, J.D. | Class I Director | Appointed | 2024-06-18 |
| Mika Derynck, M.D. | Class I Director | Appointed | 2024-06-18 |
| Lori Kunkel, MD | Class III director | Appointed | 2024-04-09 |
| Rahul Ballal | member of Enliven's board of directors | Appointed | 2023-03-01 |
| Andrew Schwab | director | Appointed | 2023-03-01 |
| Richard Heyman, Ph.D. | director | Appointed | 2023-03-01 |
| Andrew Phillips, Ph.D. | director | Appointed | 2023-03-01 |
| Rishi Gupta, J.D. | director | Appointed | 2023-03-01 |
| Mika Derynck, M.D. | director | Appointed | 2023-03-01 |
| Sam Kintz, M.B.A. | member of the Board of directors | Appointed | 2023-03-01 |
| Jake Bauer | director | Appointed | 2023-03-01 |
| Joseph Lyssikatos, Ph.D. | director | Appointed | 2023-03-01 |
| Sam Kintz, M.B.A. | President and Chief Executive Officer | Appointed | 2023-03-01 |
| Helen Collins | Chief Medical Officer | Appointed | 2023-03-01 |
| Benjamin Hohl | Chief Financial Officer | Appointed | 2023-03-01 |
| Rahul D. Ballal, Ph.D. | President and Chief Executive Officer | Resigned | 2023-03-01 |
| Michael P. Gray | Chief Financial Officer and Chief Operating Officer | Resigned | 2023-03-01 |
| Laura Williams, M.D., MPH | director | Resigned | 2023-03-01 |
| Barbara J. Dalton, Ph.D. | director | Resigned | 2023-03-01 |
| Carl Goldfischer, M.D. | director | Resigned | 2023-03-01 |
| Edward Conner, M.D. | director | Resigned | 2023-03-01 |
Key facts
CIK
1672619
CUSIP
29337E102
13F (30d)
203 filings
202 filers
Visit website
Investor relations